June 12th, 2015
YPrime announced today that its IRT platform has been selected to support an international Phase II oncology clinical trial evaluating a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). The study will leverage YPrime Interactive Response Technology (IRT) alongside its proprietary eClinical Supply Forecasting (eCSF) tool to support trial execution and global supply management.
As part of the study, YPrime provided technology to support selected international clinical trial sites with data-driven metrics designed to improve visibility into patient activity and clinical supply performance. By integrating IRT with clinical supply forecasting, YPrime helps sponsors manage enrollment, treatment allocation, and supply logistics across a global trial footprint.
YPrime’s IRT platform was implememnted to support efficient trial operations and address the operational complexity often associated with international oncology clinical trials. The company’s approach focused on improving coordination across sites while maintaining control and oversight of the clinical supply chain.
“Our team is very pleased to continue helping biotechnology and pharmaceutical companies track patient activity and ensure the clinical supply chain runs smoothly in international studies,” said Shawn Blackburn, President and Co-Founder of YPrime. “We added significant value by playing a critical role in the successful integration of eClinical solutions for this biopharmaceutical organization.”
This Phase II study reflects YPrime’s early expertise in applying IRT and clinical supply forecasting technology to complex, global clinical trials. By supporting oncology research with integrated eClinical solutions, YPrime hels sponsors and CROs improve operational execution while advancing treatments for areas of unmet medical need.
To learn more about YPrime’s industry leading IRT platform, visit www.yprime.com/irt.